Assessment of biotechnologies: a therapeutic monoclonal antibody emerging score

Abstract

This paper focuses on quantifying critical factors using expert's opinions to develop an emergence score to select/rank promising therapeutic mAbs on a patent-level using hierarchical decision model. Six attributes related to each factor concerning the patent status, patent owner's profile and the mAbs medical relevance were analyzed. Our data shows the medical relevance as the most important factor for a mAb to be considered emerging. And, among the six attributes, the most important under the patent status were geographic coverage and patent scope; for the assignee's profile, were strategic alliances and preexistence of approved drugs; and for medical relevance, the clinical phase performance and the mAb cellular mechanism were the most relevant. The results will provide enough information to rank any patent related to the field according to the emergence score defined by the attributes importance. Our data can be associated with forecasting tools such as patent analysis to improve the identification and anticipation of future innovations pathways in this sector